InsidersTradesSigma
Total declarations
Company
▲ Purchases (5 ops.)
▼ Sales (0 ops.)
Explore the full record of transactions filed by Mackaness James H, Chief Financial Officer. Director active across 1 companies, notably Soleno Therapeutics INC. Aggregated, 5 filings have been logged. Total volume traded: €35k. The latest transaction was disclosed on 13 September 2021 — Acquisition. Regulator: SEC (Form 4). The full history is free.
Declarations5 total
40,000 shares
Common Stock
SEC:0000899243-22-013308:0·
Ideal exit: 26 Dec 2022 (T+270)
€8,9106,060 shares@ €1.47030.0003% mcap51.3% of flow
Common Stock
SEC:0000899243-21-035862·
Ideal exit: 23 Mar 2021 (T+270)
€8,45011,235 shares@ €0.75210.0003% mcap48.7% of flow
Common Stock
SEC:0000899243-21-035864·
Ideal exit: 10 Jun 2022 (T+270)
€8,9106,060 shares@ €1.47030.0003% mcap25.7% of flow
Common Stock
SEC:0000899243-21-035862:0·
Ideal exit: 23 Mar 2021 (T+270)
€8,45011,235 shares@ €0.75210.0003% mcap24.3% of flow
Common Stock
SEC:0000899243-21-035864:0·
Ideal exit: 10 Jun 2022 (T+270)
5 of 5 declarations
About Mackaness James H
James H. Mackaness serves as the Chief Financial Officer at Soleno Therapeutics Inc. In this role, he is responsible for managing the company's finances, which specializes in developing treatments for rare diseases. James plays a key role in financial planning and funding strategy. His financial expertise is essential for ensuring Soleno's growth and sustainability.
